概要：Jurkat E6.1 cells are a widely used human T-cell leukemia cell line derived from a patient with acute T-cell leukemia.
The cells were first established by Schneider et al.
in 1983 from the peripheral blood of a 14-year-old boy with acute T-cell leukemia and later a derivative clone E6.1 was cloned by Dr.
Kendall Smith at the Fred Hutchinson Cancer Research Center.
The cells are characterized by their ability to proliferate rapidly and their strong responsiveness to various stimuli, including phorbol esters and either lectins or monoclonal antibodies against the T3 antigen, which are required to induce the production of Interleukin-2 (IL-2).
This makes them a useful tool for studying the activation and regulation of T-cells.
The cells contain several mutations, including the TEL-JAK2 fusion gene, which is thought to contribute to their leukemia phenotype.
Jurkat E6.1 cells have an abnormal karyotype, which is a characteristic of cancer cells.
The karyotype analysis showed that the cells have a modal chromosome number of 46, which occurs in 74% of the cells.
Additionally, there is a 5.3% of polyploidy, which is an abnormal condition where there is more than two sets of chromosomes.
The karyotype of the cells is 46,xY,-2,-18,del(2) (p21p23),del(18) (p11.2) which means that there is a deletion of the short arm of chromosome 2 and 18 respectively.
Most cells have normal x and Y chromosomes.
This karyotype is considered a hallmark of the cells and is an important characteristic to identify them.
Jurkat E6.1 cells have been used in a wide range of studies, including investigating the molecular mechanisms of T-cell activation, the role of signaling pathways in T-cell proliferation, and the development of new therapeutics for T-cell leukemia.
